Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ORVACS (Objectif Recherche VACcin Sida) is a French non-profit international research consortium dedicated to developing a functional cure for HIV. Founded by leading experts at the Pitié-Salpêtrière Hospital in Paris, the organization focuses on therapeutic vaccines and innovative immunotherapy strategies to achieve long-term viral remission without antiretroviral therapy. ORVACS collaborates extensively with academic institutions and global health organizations to conduct multi-center clinical trials. Their work primarily targets the reduction of the viral reservoir and the enhancement of the immune system's ability to control HIV. The organization is structured as an endowment fund that bridges the gap between basic research and clinical application.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ORVACS.